Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; its reference list is not available.

Improving de novo protein binder design with deep learning

Open access

Published version of a preprint

Abstract

Recently it has become possible to de novo design high affinity protein binding proteins from target structural information alone. There is, however, considerable room for improvement as the overall design success rate is low. Here, we explore the augmentation of energy-based protein binder design using deep learning. We find that using AlphaFold2 or RoseTTAFold to assess the probability that a designed sequence adopts the designed monomer structure, and the probability that this structure binds the target as designed, increases design success rates nearly 10-fold. We find further that sequence design using ProteinMPNN rather than Rosetta considerably increases computational efficiency.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-023-38328-5

Cites

Statistics

Figures

Fig. 1 Monomer and protein complex structure prediction metrics distinguish previously designed binders from non-binders. a For binder design to be successful, the designed sequence must fold to the designed binder monomer structure (left), and this structure must form the designed interface with the target protein (right). b, c Design failure modes. b Type-1 Failures. The designed sequence does not fold to the designed monomer structure. c Type-2 Failures. The designed sequence folds to the designed monomer structure but does not form the designed interface. d, e The retrospective experimental success rate (YSD SC50 < 4 μM) for the top 1% of designs selected according to different monomer (d) or protein complex (e) based metrics over 10 targets from Cao et al. Source data are provided as a Source Data file.
Fig. 1 Monomer and protein complex structure prediction metrics distinguish previously designed binders from non-binders. a For binder design to be successful, the designed sequence must fold to the designed binder monomer structure (left), and this structure must form the designed interface with the target protein (right). b, c Design failure modes. b Type-1 Failures. The designed sequence does not fold to the designed monomer structure. c Type-2 Failures. The designed sequence folds to the designed monomer structure but does not form the designed interface. d, e The retrospective experimental success rate (YSD SC50 < 4 μM) for the top 1% of designs selected according to different monomer (d) or protein complex (e) based metrics over 10 targets from Cao et al. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 2 Incorporation of structure prediction metrics increases design success rate on new targets. a Results of Prospective Campaigns. For each target the SC50 from YSD is shown for all designs which showed binding by YSD (like Kd’s, lower values are better). The number of designs included in each library for each target is indicated by the bars in the top panel. The AF2-predicted structure of the top scoring on-target design is shown as a cartoon. No binders were identified to Site 2 of IL2 receptor-ɑ so this campaign is not included here or in panel C. b The experimental success rate for libraries filtered by DL-based filtering versus Physically based filtering for the four prospective targets. c The computational efficiency (the number of designs with pAE_interaction <10 per CPU-s) for the ProteinMPNN sequence design plus Rosetta relax protocol outperforms that of the original Rosetta sequence design protocol. Source data are provided as a Source Data file.
Fig. 2 Incorporation of structure prediction metrics increases design success rate on new targets. a Results of Prospective Campaigns. For each target the SC50 from YSD is shown for all designs which showed binding by YSD (like Kd’s, lower values are better). The number of designs included in each library for each target is indicated by the bars in the top panel. The AF2-predicted structure of the top scoring on-target design is shown as a cartoon. No binders were identified to Site 2 of IL2 receptor-ɑ so this campaign is not included here or in panel C. b The experimental success rate for libraries filtered by DL-based filtering versus Physically based filtering for the four prospective targets. c The computational efficiency (the number of designs with pAE_interaction <10 per CPU-s) for the ProteinMPNN sequence design plus Rosetta relax protocol outperforms that of the original Rosetta sequence design protocol. Source data are provided as a Source Data file.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 41 · Cited by 402

Metadata

Authors
Bennett, N. R., Coventry, B., Goreshnik, I., Huang, B., Allen, A., Vafeados, D., Peng, Y. P., Dauparas, J., Baek, M., Stewart, L., DiMaio, F., De Munck, S., Savvides, S. N., & Baker, D.
Affiliations
  • University of Washington (US)
  • Howard Hughes Medical Institute (US)
  • Ghent University (BE)
Corresponding author
Baker, David
Venue
Nature Communications
Published
2023-05-06
Volume
14
Issue
1
Pages
2625-2625
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4375856225
Cited by
402
References
41
Citations by year
2026: 126 · 2025: 161 · 2024: 83 · 2023: 28
FWCI
35.35
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Howard Hughes Medical Institute
  • United States Department of Defense | Defense Advanced Research Projects Agency (HR001120S0052)
  • Microsoft
  • The Audacious Project at the Institute for Protein Design
  • The Donald and Jo Anne Petersen Endowment for Accelerating Advancements in Alzheimer’s Disease Research
  • Vlaams Instituut voor Biotechnologie
  • Fonds Wetenschappelijk Onderzoek
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
de novo protein design, protein binder design, deep learning, AlphaFold2, RoseTTAFold, ProteinMPNN, energy-based design, protein-protein binding, sequence design, computational efficiency
MeSH terms
Deep Learning, Protein Binding, Proteins, Protein Engineering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Improving de novo protein binder design with deep learning. https://app.cochat.ai/papers/10.1038/s41467-023-38328-5
The paper
Bennett, N. R., Coventry, B., Goreshnik, I., Huang, B., Allen, A., Vafeados, D., Peng, Y. P., Dauparas, J., Baek, M., Stewart, L., DiMaio, F., De Munck, S., Savvides, S. N., & Baker, D. (2023). Improving de novo protein binder design with deep learning. Nature Communications. https://doi.org/10.1038/s41467-023-38328-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.